Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle

被引:43
|
作者
Seelig, AS [1 ]
Al-Hasani, S [1 ]
Katalinic, A [1 ]
Schöpper, B [1 ]
Sturm, R [1 ]
Diedrich, K [1 ]
Ludwig, M [1 ]
机构
[1] Univ Clin Hosp, Dept Gynecol & Obstet, D-23538 Lubeck, Germany
关键词
cetrorelix; cryopreservation; GnRH agonist; GnRH antagonist; open freezing system;
D O I
10.1016/S0015-0282(01)03008-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the pregnancy rates of frozen-thawed 2-pronucleate (2PN) oocytes obtained either in a long protocol or in an antagonist protocol and ovarian stimulation with either human menopausal gonadotropin (hMG) or recombinant follicular stimulating hormone (recFSH). Design: Retrospective data analysis. Setting: Academic infertility center. Patient(s): Three hundred forty-two infertile couples who under-went a transfer of cryopreserved 2PN oocytes. Intervention(s): hMG (n = 194) or recFSH (n = 92) in a long protocol or hMG (n = 16) or recFSH (n = 40) stimulation under pituitary suppression with the GnRH antagonist Cetrotide was used. The 2PN oocytes were transferred after endometrial preparation using E, valerate and vaginal progesterone (Crinone 8% vaginal gel). Main Outcome Measure(s): Implantation, pregnancy, and abortion rates. Result(s): Implantation rates in the freeze-thaw cycles were 5.6% (hMG) and 3.8% (recFSH) with 2PN oocytes from the long protocol and 7% from the antagonist cycles, irrespective of whether hMG or reeFSH was used. Pregnancy rates were similar independent of whether they resulted from the long-protocol cycles with hMG (15.4%) and recFSH (13.1%) or from the antagonist protocol cycles with hMG (25.0%) and recFSH ( 17.5%. Conclusion(s): The potential to implant is independent of the gonadotropin-releasing hormone analogue and gonadotropin chosen for the collection cycle when previously cryopreserved 2PN oocytes were replaced after thawing in the cleavage stage. (Fertil Steril(R) 2002:77:472-5. (C)2002 by American Society for Reproductive Medicine.).
引用
收藏
页码:472 / 475
页数:4
相关论文
共 50 条
  • [31] Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs
    Huerta-Reyes, Maira
    Maya-Nunez, Guadalupe
    Allan Perez-Solis, Marco
    Lopez-Munoz, Eunice
    Guillen, Nancy
    Olivo-Marin, Jean-Christophe
    Aguilar-Rojas, Arturo
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [32] A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
    Fatemeh Sadat Hoseini
    Seyed Mohammad Hossein Noori Mugahi
    Firoozeh Akbari-Asbagh
    Poopak Eftekhari-Yazdi
    Behrouz Aflatoonian
    Seyed Hamid Aghaee-Bakhtiari
    Reza Aflatoonian
    Nasser Salsabili
    DARU Journal of Pharmaceutical Sciences, 22
  • [33] Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists
    Blumenfeld, Zeev
    Evron, Ayelet
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (07) : 1009 - 1020
  • [34] A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
    Hoseini, Fatemeh Sadat
    Mugahi, Seyed Mohammad Hossein Noori
    Akbari-Asbagh, Firoozeh
    Eftekhari-Yazdi, Poopak
    Aflatoonian, Behrouz
    Aghaee-Bakhtiari, Seyed Hamid
    Aflatoonian, Reza
    Salsabili, Nasser
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 22
  • [35] Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates
    Acevedo, Belen
    Gomez-Palomares, Jose Luis
    Ricciarelli, Elisabetta
    Hernandez, Eleuterio R.
    FERTILITY AND STERILITY, 2006, 86 (06) : 1682 - 1687
  • [36] Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer
    Liu, Yi-Fu
    Fu, Sheng-Qiang
    Yan, Yu-Chang
    Gong, Bin-Bin
    Xie, Wen-Jie
    Yang, Xiao-Rong
    Sun, Ting
    Ma, Ming
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 639 - 649
  • [37] Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting
    Yuen, Basil Ho
    Nguyen, Tuan-Anh T.
    Cheung, Anthony P.
    Leung, Peter C. K.
    FERTILITY AND STERILITY, 2009, 92 (02) : 499 - 507
  • [38] The effect of delayed initiation of gonadotropin-releasing hormone antagonist in a flexible protocol on in vitro fertilization outcome
    Tannus, Samer
    Weissman, Ariel
    Boaz, Mona
    Horowitz, Eran
    Ravhon, Amir
    Golan, Abraham
    Levran, David
    FERTILITY AND STERILITY, 2013, 99 (03) : 725 - 730
  • [39] Premature luteinization and in vitro fertilization outcome in gonadotropin/gonadotropin-releasing hormone antagonist cycles in women with polycystic ovary syndrome
    Segal, Shimon
    Glatstein, Isaac
    McShane, Patricia
    Hotamisligil, Selen
    Ezcurra, Diego
    Carson, Ronald
    FERTILITY AND STERILITY, 2009, 91 (05) : 1755 - 1759
  • [40] Gonadotropin-releasing hormone antagonist: A real advantage?
    Kimura, Takahiro
    Sasaki, Hiroshi
    Akazawa, Kouhei
    Egawa, Shin
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (07) : 322 - 328